$ABT

Morrone Louis H. sold $643K of ABT

Morrone Louis H. (EXECUTIVE VICE PRESIDENT) sold 5,850 shares of ABBOTT LABORATORIES (ABT) at $109.83 ($0.64M total) on 2026-08-11.

Original reporting
SEC EDGAR · Morrone Louis H.
Published Aug 13, 2026, 9:14 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ABT
Neutral
medium confidence
Mentioned
$ABT
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABTNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may briefly watch for sentiment effects from insider selling, but there is no accompanying fundamental catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-scheduled personal liquidity needs; the article provides no stated reason for the sale.

Relevance 5/10Novelty 3/10Timing: filed after-hours on 2026-08-13, covering a sale dated 2026-08-11

Background

The article is an SEC Form 4 insider transaction disclosure for Abbott Laboratories (ABT).

Company-level read

Ticker impact

$ABTNeutralMedium confidence
Context

Abbott Laboratories Form 4 shows EVP Morrone Louis H. sold 5,850 shares at $109.83 on 2026-08-11 for about $642.5K.

Expected impact

Low likelihood of a sustained price move; any near-term impact would be sentiment-driven and typically fades.

Evidence & confidence

The filing discloses transaction size, price, and post-sale holdings, but provides no new company-specific operational, financial, or regulatory information.

Market effects

No clear sector read-through; insider sales are common and not a sector catalyst by themselves.

None indicated.

None indicated.

Counterpoint

Because the filing states no pre-arranged 10b5-1 plan, some traders may interpret the sale as higher near-term risk, even though insider sales are often non-informational.

Key entities

  • Abbott Laboratories

    Subject of the Form 4 insider transaction disclosure.

  • Morrone Louis H.

    Executive Vice President who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ABTMedAI 8/10

Abbott settlement and Kendamil case add to formula industry scrutiny

Abbott Nutrition agreed to pay $670 million to resolve claims related to its preterm infant formulas, without admitting liability. The settlement includes a Missouri case where a jury awarded $495 million to a plaintiff. Abbott maintains its products are safe and supported by medical professionals. Separately, Abbott challenged competitor Kendamil's advertising claims, with NAD recommending Kendamil remove certain claims about nutritional benefits.

$ABTHighAI 9/10

Dual glucose-ketone tracker on the way for diabetes patients – DPA

The FDA approved Abbott Laboratories' Libre Duo 10 Day, a wearable device that continuously monitors both glucose and ketone levels. This first-of-its-kind tracker aims to prevent life-threatening emergencies like diabetic ketoacidosis (DKA) by providing real-time data. Abbott claims the device simplifies monitoring for diabetes patients, who previously had to use separate tests for ketones.

$ABTMedAI 9/10

Abbott Laboratories (ABT) Could Be 6% Below Fair Value Following Libre Duo FDA Approval

Abbott Laboratories (ABT) received FDA approval for its Libre Duo 10 Day sensor, which tracks glucose and ketone levels. The company's stock closed at $112.47, with mixed returns over different periods. Analysts suggest ABT is 5.6% undervalued, with a fair value of $119.13, citing innovation in high-margin segments. However, investors should monitor diagnostic pricing in China and potential litigation risks.

$ABTMedAI 8/10

This Week at FDA: HHS considering new FDA posts, FDA approves slew of firsts, and more

The Trump administration may add two FDA deputy commissioner roles. FDA approved first-of-kind treatments from Revolution Medicines (Rasonque for pancreatic cancer), Priovant Therapeutics (Lisraya for dermatomyositis), and Janssen Biotech (Imaavy for wAIHA). Abbott's Libre Duo 10 Day received de novo authorization for a dual glucose and ketone monitoring system. FDA issued alerts for Abiomed, Medtronic, and Boston Scientific devices, and recalls for Boston Scientific and AVID Medical products.

$ABTHighAI 9/10

How Investors Are Reacting To Abbott (ABT) Dual Glucose‑Ketone Libre Duo FDA Greenlight

Abbott Laboratories (ABT) received FDA authorization for its Libre Duo 10 Day system, a wearable that monitors glucose and ketone levels. The U.S. launch is planned for later this year. Abbott projects $60.4 billion revenue and $9.5 billion earnings by 2029. The company faces litigation and other challenges, but the new device could strengthen its diabetes platform. Analysts' fair value estimates for ABT shares range from $119 to $152.